Epigenetic Modifiers: Anti-Neoplastic Drugs With Immunomodulating Potential.
Ontology highlight
ABSTRACT: Cancer cells are under the surveillance of the host immune system. Nevertheless, a number of immunosuppressive mechanisms allow tumors to escape protective responses and impose immune tolerance. Epigenetic alterations are central to cancer cell biology and cancer immune evasion. Accordingly, epigenetic modulating agents (EMAs) are being exploited as anti-neoplastic and immunomodulatory agents to restore immunological fitness. By simultaneously acting on cancer cells, e.g. by changing expression of tumor antigens, immune checkpoints, chemokines or innate defense pathways, and on immune cells, e.g. by remodeling the tumor stroma or enhancing effector cell functionality, EMAs can indeed overcome peripheral tolerance to transformed cells. Therefore, combinations of EMAs with chemo- or immunoth
SUBMITTER: Maes K
PROVIDER: S-EPMC8042276 | biostudies-literature | 2021
REPOSITORIES: biostudies-literature
ACCESS DATA